Relationships between adiponectin levels, the metabolic syndrome, and type 2 diabetes: a literature review
Autor(a) principal: | |
---|---|
Data de Publicação: | 2017 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://dx.doi.org/10.1590/2359-3997000000316 https://repositorio.unifesp.br/handle/11600/54019 |
Resumo: | Elevated hepatic glucose production, impaired insulin secretion, and insulin resistance - abnormalities of glucose metabolism typically found in subjects with obesity - are major factors underlying the pathogenesis of type 2 diabetes (DM2) and the metabolic syndrome (MS). Adiponectin is a major regulator of glucose and lipid homeostasis via its insulin-sensitizing properties, and lower levels seems to be associated with the development of DM2 and MS. The purpose of this review is to clarify the mechanisms whereby adiponectin relates to the development of DM2 and MS and the association between polymorphisms of the adiponectin gene, circulating levels of the hormone, and its relationships with DM2. In addition, the impact of dietary lipids in the circulating levels of adiponectin will be addressed. According to the literature, circulating adiponectin levels seem to decrease as the number of MS components increases. Lower adiponectin concentrations are associated with higher intra-abdominal fat content. Therefore, adiponectin could link intra-abdominal fat with insulin resistance and development of MS. Therapeutic strategies that target the MS and its components, such as lifestyle modification through physical activity and weight loss, have been shown to increase adiponectin concentrations. Possible roles of diets containing either low or high amounts of fat, or different types of fat, have been analyzed in several studies, with heterogeneous results. Supplementation with n-3 PUFA modestly increases adiponectin levels, whereas conjugated linoleic acid supplementation appears to reduce concentrations when compared with unsaturated fatty acid supplementation used as an active placebo. |
id |
UFSP_cf6e3d6392a8511c91b872d32dd80f29 |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br/:11600/54019 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Relationships between adiponectin levels, the metabolic syndrome, and type 2 diabetes: a literature reviewAdiponectinmetabolic syndrometype 2 diabetesElevated hepatic glucose production, impaired insulin secretion, and insulin resistance - abnormalities of glucose metabolism typically found in subjects with obesity - are major factors underlying the pathogenesis of type 2 diabetes (DM2) and the metabolic syndrome (MS). Adiponectin is a major regulator of glucose and lipid homeostasis via its insulin-sensitizing properties, and lower levels seems to be associated with the development of DM2 and MS. The purpose of this review is to clarify the mechanisms whereby adiponectin relates to the development of DM2 and MS and the association between polymorphisms of the adiponectin gene, circulating levels of the hormone, and its relationships with DM2. In addition, the impact of dietary lipids in the circulating levels of adiponectin will be addressed. According to the literature, circulating adiponectin levels seem to decrease as the number of MS components increases. Lower adiponectin concentrations are associated with higher intra-abdominal fat content. Therefore, adiponectin could link intra-abdominal fat with insulin resistance and development of MS. Therapeutic strategies that target the MS and its components, such as lifestyle modification through physical activity and weight loss, have been shown to increase adiponectin concentrations. Possible roles of diets containing either low or high amounts of fat, or different types of fat, have been analyzed in several studies, with heterogeneous results. Supplementation with n-3 PUFA modestly increases adiponectin levels, whereas conjugated linoleic acid supplementation appears to reduce concentrations when compared with unsaturated fatty acid supplementation used as an active placebo.Univ Fed Rio Grande do Sul, Fac Med, Programa Posgrad Endocrinol, Porto Alegre, RS, BrazilUFCSPA, Dept Nutr, Porto Alegre, RS, BrazilUniv Fed Sao Paulo Unifesp, Dept Med, Disciplina Endocrinol, Sao Paulo, SP, BrazilHCPA, Div Endocrinol, Unidade Metab, Porto Alegre, RS, BrazilUniv Fed Sao Paulo Unifesp, Dept Med, Disciplina Endocrinol, Sao Paulo, SP, BrazilWeb of ScienceState of Rio Grande do Sul Foundation for Research Support [Fapergs PG 5989.284.18921.12062013]Hospital de Clinicas de Porto Alegre Research and Event Incentive Fund [FIPE-HCPA 11-226]Brazilian National Research Council [CNPq 486802/2013-2][Fapergs PG 5989.284.18921.12062013]Hospital de Clinicas de Porto Alegre Research and Event Incentive Fund [FIPE-HCPA 11-226][CNPq 486802/2013-2]Sbem-Soc Brasil Endocrinologia & Metabologia2020-07-02T18:52:21Z2020-07-02T18:52:21Z2017info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion614-622application/pdfhttp://dx.doi.org/10.1590/2359-3997000000316Archives Of Endocrinology Metabolism. Rio De Janeiro, Rj, v. 61, n. 6, p. 614-622, 2017.10.1590/2359-3997000000316WOS000424375800016.pdf2359-3997https://repositorio.unifesp.br/handle/11600/54019WOS:000424375800016engArchives Of Endocrinology MetabolismRio De Janeiro, Rjinfo:eu-repo/semantics/openAccessvon Frankenberg, Anize DelfinoReis, Andre F. [UNIFESP]Gerchman, Fernandoreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-08-11T04:01:17Zoai:repositorio.unifesp.br/:11600/54019Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-08-11T04:01:17Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.none.fl_str_mv |
Relationships between adiponectin levels, the metabolic syndrome, and type 2 diabetes: a literature review |
title |
Relationships between adiponectin levels, the metabolic syndrome, and type 2 diabetes: a literature review |
spellingShingle |
Relationships between adiponectin levels, the metabolic syndrome, and type 2 diabetes: a literature review von Frankenberg, Anize Delfino Adiponectin metabolic syndrome type 2 diabetes |
title_short |
Relationships between adiponectin levels, the metabolic syndrome, and type 2 diabetes: a literature review |
title_full |
Relationships between adiponectin levels, the metabolic syndrome, and type 2 diabetes: a literature review |
title_fullStr |
Relationships between adiponectin levels, the metabolic syndrome, and type 2 diabetes: a literature review |
title_full_unstemmed |
Relationships between adiponectin levels, the metabolic syndrome, and type 2 diabetes: a literature review |
title_sort |
Relationships between adiponectin levels, the metabolic syndrome, and type 2 diabetes: a literature review |
author |
von Frankenberg, Anize Delfino |
author_facet |
von Frankenberg, Anize Delfino Reis, Andre F. [UNIFESP] Gerchman, Fernando |
author_role |
author |
author2 |
Reis, Andre F. [UNIFESP] Gerchman, Fernando |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
von Frankenberg, Anize Delfino Reis, Andre F. [UNIFESP] Gerchman, Fernando |
dc.subject.por.fl_str_mv |
Adiponectin metabolic syndrome type 2 diabetes |
topic |
Adiponectin metabolic syndrome type 2 diabetes |
description |
Elevated hepatic glucose production, impaired insulin secretion, and insulin resistance - abnormalities of glucose metabolism typically found in subjects with obesity - are major factors underlying the pathogenesis of type 2 diabetes (DM2) and the metabolic syndrome (MS). Adiponectin is a major regulator of glucose and lipid homeostasis via its insulin-sensitizing properties, and lower levels seems to be associated with the development of DM2 and MS. The purpose of this review is to clarify the mechanisms whereby adiponectin relates to the development of DM2 and MS and the association between polymorphisms of the adiponectin gene, circulating levels of the hormone, and its relationships with DM2. In addition, the impact of dietary lipids in the circulating levels of adiponectin will be addressed. According to the literature, circulating adiponectin levels seem to decrease as the number of MS components increases. Lower adiponectin concentrations are associated with higher intra-abdominal fat content. Therefore, adiponectin could link intra-abdominal fat with insulin resistance and development of MS. Therapeutic strategies that target the MS and its components, such as lifestyle modification through physical activity and weight loss, have been shown to increase adiponectin concentrations. Possible roles of diets containing either low or high amounts of fat, or different types of fat, have been analyzed in several studies, with heterogeneous results. Supplementation with n-3 PUFA modestly increases adiponectin levels, whereas conjugated linoleic acid supplementation appears to reduce concentrations when compared with unsaturated fatty acid supplementation used as an active placebo. |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017 2020-07-02T18:52:21Z 2020-07-02T18:52:21Z |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1590/2359-3997000000316 Archives Of Endocrinology Metabolism. Rio De Janeiro, Rj, v. 61, n. 6, p. 614-622, 2017. 10.1590/2359-3997000000316 WOS000424375800016.pdf 2359-3997 https://repositorio.unifesp.br/handle/11600/54019 WOS:000424375800016 |
url |
http://dx.doi.org/10.1590/2359-3997000000316 https://repositorio.unifesp.br/handle/11600/54019 |
identifier_str_mv |
Archives Of Endocrinology Metabolism. Rio De Janeiro, Rj, v. 61, n. 6, p. 614-622, 2017. 10.1590/2359-3997000000316 WOS000424375800016.pdf 2359-3997 WOS:000424375800016 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Archives Of Endocrinology Metabolism |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
614-622 application/pdf |
dc.coverage.none.fl_str_mv |
Rio De Janeiro, Rj |
dc.publisher.none.fl_str_mv |
Sbem-Soc Brasil Endocrinologia & Metabologia |
publisher.none.fl_str_mv |
Sbem-Soc Brasil Endocrinologia & Metabologia |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
biblioteca.csp@unifesp.br |
_version_ |
1814268440824774656 |